Sponsors (2)
The bill speeds patient access to drugs and trials and reduces development duplication—potentially boosting U.S. competitiveness—at the cost of diminished independent domestic review, possible safety and oversight trade‑offs, and economic risks passed to patients and taxpayers.
Patients with immediately life‑threatening or chronic conditions can get faster access to approved foreign-authority drugs and trials, shortening wait times for potentially lifesaving treatments.
U.S. drug sponsors and the biopharma sector can reduce duplicate reviews, speed time‑to‑market, and help preserve high‑skilled jobs and innovation-led economic activity.
FDA must finalize labeling and required postmarket study plans quickly (30 days), giving clinicians clearer guidance soon after reciprocal authorization.
Patients may face increased safety risks because reciprocal approvals and fast deadlines can reduce the depth of independent U.S. regulatory review before market entry.
Relying on foreign regulator decisions exposes U.S. patients to differing approval standards and postmarket surveillance practices, complicating safety monitoring and follow‑up.
Shifting toward reciprocal approvals could weaken FDA's independent authority and oversight consistency, creating governance and legal challenges.
Based on analysis of 4 sections of legislative text.
Creates a fast-track "reciprocal" regulatory pathway so drugs and biologics already authorized in specified trusted foreign jurisdictions can be treated as having U.S. approval for use in immediately life‑threatening diseases and allows U.S. clinical trials to proceed based on an equivalent foreign trial authorization. The Health Secretary must act on requests within 30 days, may withdraw approvals for safety concerns, and must report to Congress after five years on program outcomes. The measure sets eligibility rules (must not already be approved in the U.S.; must be authorized by a designated trusted regulator such as EMA, UK MHRA, or Health Canada; must address an immediately life‑threatening condition), requires translated regulatory dossiers, treats requests as fee‑bearing FDA submissions, and creates near‑term timelines and postmarket safeguards for rapid patient access while preserving the Secretary's authority to suspend or withdraw authorizations if safety issues arise.
Introduced March 17, 2026 by Pete Sessions · Last progress March 17, 2026